The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute a simple solution

Intensive Care Med. 2022 Aug;48(8):1116-1117. doi: 10.1007/s00134-022-06744-8. Epub 2022 May 25.

Authors

Johannes Gratz¹, Marion Wiegele¹, Christoph Dibiasi¹, Eva Schaden^{2

3}

Affiliations

¹ Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Vienna, Austria.
² Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Vienna, Austria. [email protected].
³ Ludwig Boltzmann Institute for Digital Health and Patient Safety (LBG), Vienna, Austria. [email protected].

PMID: 35614321
DOI: 10.1007/s00134-022-06744-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Anticoagulants* / pharmacology
Anticoagulants* / therapeutic use
Factor Xa Inhibitors / therapeutic use
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Intensive Care Units
Venous Thromboembolism* / drug therapy
Venous Thromboembolism* / prevention & control

Substances

Anticoagulants
Factor Xa Inhibitors
Heparin, Low-Molecular-Weight